Entrada Therapeutics ( TRDA ) reported a 3Q25 GAAP EPS loss of -$1.06 along with a revenue figure of$1.6 million. Since earnings on November 6th, the stock is up about 25%. In the report, there was a pretty sharp declineI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciatio ...